Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (SMART-C)
The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified. There will be two arms – one arm will have two on-treatment clinic visits; the other arm will have no on-treatment clinic visits.
This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus (HCV) therapy with grazoprevir/elbasvir, will be feasible for the treatment of People who inject drugs (PWID) with recent injecting drug use and chronic HCV genotype 1 or 4 infection.
The study is recruiting people newly with infected hepatitis C to treat them with the combination of sofosbuvir plus ribavirin for a treatment period of 6 weeks. The study is evaluating the safety and effectiveness of sofosbuvir plus ribavirin.
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-CII)
To read the entire clinical trial description, click here…